The relentless coronavirus disease (COVID-19) pandemic quickly prompted the pursuit of novel effective therapeutic agents against the highly virulent SARS-CoV-2 virus. One of the prime targets for researchers is the angiotensin-converting enzyme 2 (ACE2), the primary receptor for SARS-CoV-2 spike glycoprotein (S1 subunit), which mediates viral entry into host cells. Read More
top of page
bottom of page